May 1, 2018 02:13 PM EDT

‘Biohacker’ Traywick dead at 28 — known for self-injecting a DIY herpes drug

Amber Tong

Controversial biohacker Aaron Traywick was found dead on Sunday in a spa room in Washington, DC, according to multiple media reports citing the DC police …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

‘Biohacker’ Traywick dead at 28 — known for self-injecting a DIY herpes drug

Amber Tong

Sign up to read this article for free.

CagriSema’s weight loss data disappointed. What does Novo do next?

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

CMS explains what went into its first round of drug price negotiations

WuXi AppTec will sell cell and gene therapy business to private equity firm

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

Three drugmakers sue US over 340B discounts to STD clinics they allege don’t qualify

‘Bio­hack­er’ Tray­wick dead at 28 — known for self-in­ject­ing a DIY her­pes drug

Amber Tong

Sign up to read this article for free.

more like this

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

‘Biohacker’ Traywick dead at 28 — known for self-injecting a DIY herpes drug

CagriSema’s weight loss data disappointed. What does Novo do next?

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

CMS explains what went into its first round of drug price negotiations

WuXi AppTec will sell cell and gene therapy business to private equity firm

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

Three drugmakers sue US over 340B discounts to STD clinics they allege don’t qualify